S&P Futures
3,851.00 +2.75 (+0.07%) Dow Futures
31,038.00 +25.00 (+0.08%) Nasdaq Futures
11,896.75 +16.50 (+0.14%) Russell 2000 Futures
1,731.60 +3.00 (+0.17%) Crude Oil
99.23 +0.70 (+0.71%) Gold
1,743.80 +7.30 (+0.42%)
Arcus Biosciences, Inc. (RCUS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 28.59 |
| Open | 28.36 |
| Bid | 11.44 x 1100 |
| Ask | 29.99 x 1000 |
| Day's Range | 28.30 - 29.61 |
| 52 Week Range | 16.74 - 49.10 |
| Volume | |
| Avg. Volume | 1,122,631 |
| Market Cap | 2.049B |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | 31.74 |
| EPS (TTM) | 0.90 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.20 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RCUS
Related Research
- Arcus Biosciences, Inc.RCUS: What does Argus have to say about RCUS?ARCUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $19.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat8 days agoArgus Research
- Simply Wall St.
Arcus Biosciences, Inc.'s (NYSE:RCUS) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Most readers would already be aware that Arcus Biosciences' (NYSE:RCUS) stock increased significantly by 40% over the...
- Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif., June 24, 2022--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 22,850 shares of the Company’s common stock at an exercise price per share of $24.98, which was the closing price on June 23, 2022, and restricted stock units to acquire a total of 11,425 shares
- Business Wire
Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
HAYWARD, Calif., May 31, 2022--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California. The fireside chat will take place on Thursday, June 16th, 2022 at 9:20 a.m. PT.
